A growing U.S. shortage of Adderall, a prescription drug taken to treat attention deficit hyperactivity disorder, has spread to two more makers of the drug. Lannett Co. and Par Pharmaceuticals are the most recent companies experiencing with limited supplies of generic extended-release Adderall, according to the University of Utah Pharmacy Services website, which tracks drug shortages nationwide More than six in 10 small pharmacies reported having difficulty in August obtaining the medication, a survey from the National Community Pharmacists Association found. Lannett spokesperson Robert Jaffe confirmed to USA TODAY Wednesday the company is seeing spikes in demand for its 15-milligram extended-release pills. Quotas on how much Adderall can be made also affects supply, Jaffe said.
Adderall Shortage in US Spreads to Two More Drug Suppliers, Impacting Consumer Demand
by Dan DeMarle | Dec 19, 2022 | ADHD, Attention Deficit Hyperactivity Disorder, Medicine, Other Health Impairment